Abstract Chromosomal instability is a known hallmark of many cancers. DNA polymerases represent a group of enzymes that are involved in the mechanism of chromosomal instability as they have a central function in DNA metabolism. We hypothesized that genetic variation in the polymerase genes may affect gene expression or protein configuration and by that cancer risk and clinical outcome. We selected four genes encoding for the catalytic subunits of the polymerases b, d, h and f (POLB, POLD1, POLQ and REV3L, respectively) and two associated proteins (MAD2L2 and REV1) because of their previously reported association with chromosomal instability and/or tumorigenesis. We selected potentially functional and most informative tagging single nucleotide polymorphisms (SNPs) for genotyping in a population-based series of 783 Swedish breast cancer (BC) cases and 1562 controls. SNPs that showed a significant association in the Swedish population were additionally genotyped in a Polish population consisting of 506 familial/ early onset BC cases and 568 controls. SNPs in all three polymerase f subunit genes associated either with BC risk or prognosis. Two SNPs in REV3L and one SNP in MAD2L2 associated with BC risk: rs462779 (multiplicative model: OR 0.79, 95% CI 0.68-0.92), rs3204953 (dominant model: OR 1.28, 95% CI 1.05-1.56) and rs2233004 (recessive model: OR 0.49, 95% CI 0.28-0.86). Homozygous carriers of the minor allele C of the third SNP in REV3L, rs11153292, had significantly worse survival compared to the TT genotype carriers (HR 2.93,). Minor allele carriers of two REV1 SNPs (rs6761391 and rs3792142) had significantly more often large tumours and tumours with high histological grade and stage. No association was observed for SNPs in POLB, POLQ and POLD1. Altogether, our data suggest a significant role of genetic variation in the polymerase f subunit genes regarding the development and progression of BC.
repair, recombination and translesion synthesis (TLS) and with that ensure faithful transmission of genetic information from one generation to the next [1] [2] [3] [4] . As a dysfunction within these genes might have severe influences, DNA polymerase genes represent potential candidates for cancer genes. A total number of 15 enzymes with a known DNA synthesis activity exist. Some of these polymerases, the socalled classic DNA polymerases [3] , are involved in rapid, high-fidelity replication of most of the eukaryotic genome, but are not capable of working on sites of DNA damage [5] . That often leads to a blockage of DNA synthesis with a stalled replication fork [6] . The arrest of DNA replication might even influence the ability of the cells to complete the cell cycle, and as a consequence it induces multiple mechanisms collectively referred to as DNA-damage-tolerance mechanism [2] . Several specialized DNA polymerases, the so-called TLS DNA polymerases [3] , are involved in this process, and they allow strand extension across template lesions [2] . Despite their special function across template lesions, when operating on undamaged DNA or non-cognate lesions, the TLS polymerases show a considerably reduced fidelity. Thus, both over-and underexpression of these polymerases can lead to an increased mutation rate, suggesting that they could potentially act both as oncogenes and tumour suppressor genes, respectively [7, 8] . Loss of specific DNA polymerases has been reported to cause chromosomal instability in mammalian cells [6] and chromosomal unstable cancers are likely to have a poorer prognosis than diploid cancers [9, 10] . The degree of aneuploidy has been shown to correlate with the severity of the disease [11] .
We hypothesized, that common genetic variation in the form of SNPs in genes encoding classic or TLS DNA polymerases could affect DNA replication by influencing gene expression or protein configuration. This might increase the level of mutations and influence cellular transformation and in the end affect cancer risk and clinical outcome. We focused on four genes encoding the catalytic subunits of two classical polymerases, polymerase d (POLD1) and polymerase b (POLB), and two TLS-polymerases, polymerase f (REV3L) and polymerase h (POLQ). These polymerases have already been reported to be involved in different types of cancer or causing chromosomal instability [4, 6-8, 12, 13] . In a second selection round, we selected SNPs in the genes MAD2L2 and REV1. The encoded proteins act as a subunit (MAD2L2) and a scaffold protein (REV1) for the polymerase f enzyme [13, 14] . We selected putatively functional SNPs and most informative tagging SNPs (tagSNPs) from these six genes and genotyped them in a population-based series of 783 Swedish BC cases with detailed clinical data and up to 15 years of follow-up together with 1562 age and gender matched controls. SNPs that showed a significant association in the Swedish population were also genotyped in a Polish population consisting of 506 familial/early onset BC cases with corresponding clinical data and 568 controls.
Materials and methods

Study populations
All selected SNPs were genotyped in a Swedish study population consisting of 783 BC cases and 1562 controls. Seven hundred forty-nine cases with age and gender matched controls were drawn from the population-based Västerbotten intervention project and the mammary screening project, which contain blood samples collected between January 1990 and January 2001 from an ethnically homogenous population living in a geographically defined region in North Sweden [15] . Prospective cases were identified from the cohorts by record linkage to the regional cancer registry. The controls were selected from the same cohort as the corresponding case. They were matched with the case by age at baseline (±6 months) and the time of sampling (±2 months). The controls had to be alive at the time of diagnosis of the corresponding case and without any previous cancer diagnosis, except carcinoma in situ of cervix uteri. Thirty-three samples were collected consecutively during the same time period from untreated patients referred to the Department of Oncology for newly diagnosed BC. Their controls, also matched for age and gender, were selected from the Västerbotten intervention cohort. The genotyping for this study was performed blinded by the case-control status of each sample using whole genome amplified DNA as described by Brendle et al. [16] . Clinical data for the unselected BC cases was retrieved from the registry managed by the Northern Sweden Breast Cancer Group (Table 1) . Information about the date of death was collected from the Swedish population register with a BCspecific follow-up until 31 December 2004. The median follow-up time was 4.7 years.
In order to investigate whether the SNPs that showed a significant association in the Swedish population also show an association in a population with familial/early onset BC, we genotyped a second population consisting of 506 familial/early onset BC cases and 568 regionally and ethnically matched controls [17] . The cases were collected through the Chemotherapy Clinics, the Genetic Counselling Service and the Surgery Clinics (Gliwice, Poland) between the years 1997 and 2009. Only cases without BRCA1/2 mutations were included in the study. Clinical data was available for 475 cases (Table 1) . Follow-up was performed until 31 December 2009. The median follow-up time after surgery was 4.1 years. We used event-free survival (EFS) as the clinical endpoint. EFS was defined as the time from surgery to the occurrence of a breast event (i.e. local or distant recurrence, contralateral BC or death due to any cause).
All participants gave informed consent to the use of their samples for research purpose. The study was approved by the ethical committees of the participating institutes.
Selection of SNPs
We focused on four genes encoding for the catalytic subunits of the polymerases b, d, h and f (POLB, POLD1, POLQ and REV3L, respectively), and two associated genes, MAD2L2 and REV1. SNPs with a minor allele frequency (MAF) of C0.1 located in promoters (up to 1 kb upstream of transcription start), 3 0 UTRs, reported nonsynonymous (ns) SNPs and most informative tagSNPs, were selected in these genes using data for the CEU population (Utah residents with Northern and Western European ancestry from the CEPH-Centre d'Etude du Polymorphisme Human population) from the International HapMap Project (http://www.hapmap.org/) and the NCBI dbSNP database (http://www.ncbi.nlm.nih.gov/snp). TagSNPs were selected using the plug-in tagSNP picker incorporated in the HapMap function \Bulk data download[ (http://hapmap. ncbi.nlm.nih.gov/downloads/index.html.en). They were sequenced for verification in a set of 32 BC samples as described earlier by Vaclavicek et al. [18] .
Promoter polymorphisms within or close to transcription factor binding sites may alter gene expression and contribute to tumorigenesis. To identify putative transcription factor binding sites we used the TESS-Transcription Element Search System tool (http://www.cbil.upenn.edu/tess/). SNPs located in the 3 0 UTR of the genes may have an effect on microRNA binding sites. MicroRNAs can down-regulate protein translation or even degrade mRNA. To identify putative microRNA binding sites we used the microR-NA.org prediction tool (http://www.microrna.org/micro rna/getGeneForm.do). nsSNPs were included in our analyses due to their potential effect on protein function. The SIFT (Sorting Intolerant from Tolerant) prediction tool (http://sift.jcvi.org/) was used to predict a possible impact of an amino acid substitution on the structure and function of human proteins [19, 20] . Additionally, an estimation of the impact of the different SNPs according to their linkage disequilibrium (LD) with other SNPs was done using the Haploview software [21] . Verified SNPs and the SNPs selected for genotyping are documented in Table 2 .
Genotyping
Genotyping was performed using an allele-specific PCRbased KASPar SNP Genotyping System purchased from KBiosciences (Hoddesdon, Great Britain). Thermocycling was performed according to the KBiosciences' PCR conditions. Detection was performed using an ABI PRISM 7900 HT Sequence Detection System with SDS 2.2 software (Applied Biosystems, Weiterstadt, Germany). The Swedish sample set contained 104 duplicate samples as quality controls for the KASPar assays. For less than 0.1% the genotypes of the duplicate samples did not agree with each other.
Statistical analysis
The observed genotype frequencies in the controls were tested for Hardy-Weinberg equilibrium (HWE) using the v 2 test. Statistical significance for a different genotype distribution in cases and controls was determined by global v 2 test. When the overall genotype effect of a SNP on the risk of BC or a clinical factor was statistically significant at the level of 0.05, the best model to represent the relationship between the genotypes and the risk of BC or a clinical factor, respectively, was selected based on likelihood ratio tests (LRTs). Odds ratios (ORs) and 95% confidence intervals (95% CIs) for associations between genotypes, BC risk and tumour characteristics were calculated by logistic regression (PROC LOGISTIC, SAS Version 9.2; SAS Institute, Cary, NC). The joint analysis was carried out using Mantel-Haenszel adjustment. Haplotypes and diplotypes were estimated and compared using the Haplotypes procedure of SAS/Genetics (SAS Version 9.1). The frequency of a specific haplotype or diplotype (haplotype pair) was estimated by summing the carrier probability for all women. The relationship between haplotypes/diplotypes and BC was assessed by logistic regression with the most common haplotype/diplotype as the reference. Gene-gene interaction was analysed by pairwise interaction using logistic regression. The survival curves for the BC-specific survival were derived by Kaplan-Meier method (PROC LIFETEST, SAS Version 9.2, SAS Institute). The relative risk of death by BC was estimated as hazard ratio (HR) using Cox regression (PROC PHREG, SAS Version 9.2, SAS Institute). In the Swedish population, censoring events were death by another cause than BC, moving out of the study and 31 December 2004. In the Polish study, cases without a breast event on 31 December 2009 were censored. The HRs were also calculated within subgroups of cases with a similar manifestation of a clinical factor. Furthermore, the hazard ratios were adjusted for the clinical factors (oestrogen and progesterone receptor status, tumour size, lymph node metastasis, histological grade) to determine the value of the genotypes as an independent prognostic marker.
Results
SNPs in REV3L and MAD2L2 associate with BC risk in the Swedish study population
The global v 2 test indicated a significant association for two SNPs in REV3L and one SNP in MAD2L2 with BC susceptibility (Table 3) Gene-gene interaction studies between REV3L and MAD2L2 with risk associated alleles showed no evidence for epistasis (data not shown). SNPs in POLB, POLQ and POLD1 were not associated with BC susceptibility (Table 3) .
None of the associations were replicated in the Polish population, which contained familial/early onset BC cases, at a statistically significant level. However, in the joint analysis the ORs remained statistically significant (Table 3) .
Association of REV3L SNPs rs11153292 and rs462779 with survival
For the tagSNP rs11153292, located in intron 6 of REV3L, an association with BC-specific survival was observed. Homozygous carriers of the minor allele C had a significantly worse survival compared to the TT genotype carriers (HR 2.93, 95% CI 1.34-6.44) ( Table 4 , Fig 1A) . After adjustment for tumour size, lymph node metastasis, histological grade, oestrogen and progesterone receptor status, the HR was 3.95 (95% CI 1.18-13.22) (Table 4) , indicating the value of rs11153292 as an independent prognostic marker. The survival was poor especially for women with the CC genotype and aggressive tumours (positive lymph node metastasis: HR 4.20, 95% CI 1.32-13.44, histological Table 3 Association of the SNPs selected in polymerase and polymerase associated genes with BC susceptibility in the Swedish study population. SNPs that showed a significant association in the Swedish population were also genotyped in the Polish population For the SNPs with a significant association, the best model was calculated. For the SNPs with genotyping information for both populations, a joint analysis was performed
Results of the best model and the statistically significant associations at 5% level are indicated in bold grade 3: HR 4.70, 95% CI 1.52-14.57, stage II-IV: HR 3.20, 95% CI 1.23-8.32) (Fig. 1b-d) . The REV3L nsSNP rs462779 was associated with survival in patients with aggressive tumours. The CC genotype carriers had worse survival than the common TT genotype carriers (positive lymph node metastasis: HR 4.15 95% CI 1.18-14.62; histological grade 3: HR 3.37 95% CI 1.12-10.08; stage II-IV: HR 3.51 95% CI 1.20-10.23), although the association with disease-free survival was not statistically significant among all BC patients (HR 2.23 95% CI 0.78-6.38). None of the other SNPs associated with survival. No association with EFS in the Polish population was observed.
Association of REV1 SNPs rs6761390 and rs3792142 with tumour characteristics When we examined the genotype distribution by tumour characteristics at the time of diagnosis, significant associations were observed for the REV1 SNPs rs6761390, rs3792136, rs3792142 and rs4341989 ( Supplementary  Tables 1, 2) . Minor allele carriers of the SNPs rs6761390 and rs3792142 had more often large tumours and tumours with high histological grade and stage than the common homozygotes. LD analysis indicated that these two SNPs were in complete LD. This was previously not known as only genotype information from two different European populations, CEU for rs3792142 and CEPH for rs6761390, was available. For rs3792136, carriers of the minor allele were more likely to have small tumours and stage 0 ? I tumours than the CC carriers. Minor allele carriers of rs4341989 had more often hormone receptor positive tumours than the common homozygotes. These SNPs were not associated with tumour characteristics in the Polish population. No other associations with tumour characteristics were observed.
Discussion
Chromosomal instability is a characteristic of almost all human cancers [22] . The degree of chromosomal instability has been shown to predict clinical outcome and discern prognostically relevant BC subtypes [10] . The strength of our study lies in the selection of six polymerase subunit genes according to their previously reported association with chromosomal instability and/or tumorigenesis. We focused on SNPs with the highest probability of an influence on gene transcription or protein product, and on the most informative We showed that genetic variation in genes encoding for the polymerase f subunits REV3L, MAD2L2 and REV1 had a statistically significant influence on BC risk and the outcome of the disease. Two SNPs in REV3L associated with BC risk, one of these was additionally associated with survival for patients with aggressive tumours. A third SNP might even represent an independent prognostic marker. One SNP in MAD2L2 associated with BC risk. Several SNPs in REV1 associated with tumour characteristics.
REV3L encodes for the catalytic subunit of polymerase f. Wittschieben et al. reported that loss of REV3L expression could contribute to genomic instability during neoplastic transformation and progression [6] and Brondello et al. reported that REV3L depletion leads so genomic instability through double-strand break accumulation [8] . REV3L has also been reported to have a lower expression in tumour versus normal tissue from early to late stages of colon carcinoma [8] . These findings provide evidence for a role of REV3L as a tumour suppressor gene.
The two SNPs in REV3L, which associated with BC risk, are nsSNPs: rs462279 leads to an amino acid change from threonine to isoleucine, rs3204953 from valine to isoleucine. However, no functional effect on the coded protein was predicted for any SNP by the SIFT prediction tool, nor did the three 3 0 UTR SNPs that were captured by the two nsSNPs change the binding sites for any microRNA. The third SNP, rs11153292, in REV3L associated with survival with homozygous carriers of the minor allele C having a worse survival compared with the common homozygotes. The strongest association was observed in patients with aggressive tumours (lymph node metastasis and high stage tumours). rs11153292 is a highly informative intronic tagSNP capturing 41 other intronic SNPs, with unknown function.
In MAD2L2, an association of the SNP rs2233004 with BC risk was observed. This promoter SNP is not in LD with any other SNP. The G-allele of the SNP creates an additional binding site for the transcription factor CCAAT enhancer binding protein alpha (CEBPA) (TFSEARCH). However, the homozygous minor allele genotype that was associated with risk was very rare with a frequency of 2 and 4% in cases and controls, respectively, minimizing the power of this result. The two other promoter SNPs genotyped in MAD2L2 were not associated with BC risk. In our previous case-control study, the most common MAD2L2 promoter SNP rs2233006 was not associated with familial BC [18] . Thus, genetic variation in the promoter of MAD2L2 does not seem to affect strongly on BC risk.
In REV1, rs6761390 and rs3792142, which were in complete LD, associated with tumour size, histological grade and stage. rs6761390 is located in the promoter of the REV1 gene, rs3792142 in intron 5. Additionally, they capture three intron 1 SNPs, rs4143760, rs1011633 and rs896249. Only for rs4143760 a change of a transcription None of the associations between the genotyped SNPs and BC risk, tumour characteristics and survival in the Swedish study population were confirmed in the Polish study population at a statistically significant level. The main difference in the study populations lies in the selection criteria for the cases. The Swedish study is a population-based study, whereas the Polish study comprises of cases with a family history of BC or an early onset of the disease. The sample sets show a significant difference in the median age of the cases (Swedish 58 years; Polish 43 years). Additionally, the survival probabilities for the Polish cases were calculated using any breast event as the clinical endpoint compared with death due to BC for the Swedish population. Thus, the lack of association in the Polish population may not necessarily indicate a lack of association with death due to BC, but a lack of association with BC progression. We selected the genes for the present study based on their known association with chromosomal instability. Chromosomal instability is common in both sporadic and hereditary cancer. In hereditary cancers, the presence of chromosomal instability has been linked to mutations in DNA repair genes [22] . Germline mutations in BRCA1, BRCA2, PALB2, NBS1, WRN, BLM and RECQL4, all of which have been linked to the repair of DNA doublestrand breaks or DNA interstrand cross-links, have been reported to predispose to the development of various chromosomal instable hereditary cancers [22] [23] [24] [25] . Contrary to hereditary cancers, the molecular basis of chromosomal instability in sporadic cancers could not yet be described [22] . These data indicate that different mechanisms influence chromosomal instability in hereditary and sporadic cancers, giving a possible explanation for the difference in our results for the Polish and Swedish study population.
For the genes POLB, POLD1 and POLQ, there was no association of the selected SNPs with BC susceptibility, tumour characteristics or survival in the Swedish sample set. Similar results were obtained by Han et al. [26] . Taking our results on mainly postmenopausal women and the results of Han et al. in premenopausal women into account, we can exclude, with a high probability any effect of common genetic variation within these genes on BC susceptibility and prognosis.
Altogether, all three genes encoding polymerase f subunits showed an association either with BC susceptibility, progression or survival. Further analysis to explain the functional consequences of the SNPs on gene expression and on BC progression are warranted.
